Loading...
XHEL
REG1V
Market cap409mUSD
Aug 03, Last price  
12.74EUR
1D
4.26%
1Q
-5.63%
Jan 2017
25.39%
IPO
2,148.22%
Name

Revenio Group Oyj

Chart & performance

D1W1MN
XHEL:REG1V chart
P/E
21.30
P/S
3.38
EPS
0.60
Div yield, %
3.27%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
12.43%
Revenues
110m
+5.99%
18,444,36011,456,00045,146,00029,977,00029,434,00033,281,00025,382,00025,727,00016,031,00020,250,00023,434,00026,791,00030,658,00049,474,00061,067,00078,778,00096,976,00096,576,000103,500,000109,700,000
Net income
17m
-5.93%
02,272,0002,665,000-815,000-507,0003,911,000-287,0004,338,000-694,0006,497,0005,584,0006,850,0008,103,0009,343,00013,362,00017,321,00021,753,00019,109,00018,497,00017,400,000
CFO
30m
+26.50%
01,001,0003,279,0001,956,0001,274,0004,229,000774,0005,483,0002,763,0006,811,0006,046,0007,870,00010,416,00012,489,00015,230,00021,509,00023,241,00010,862,00023,874,00030,200,000
Dividend
Apr 11, 20250.4 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Revenio Group Oyj operates as a healthcare technology company, specializing in the development, production, and global distribution of advanced ophthalmic diagnostic instruments and medical devices. These innovations are engineered to aid in the identification of various eye conditions, including glaucoma, macular degeneration, diabetic retinopathy, and cataracts, serving clientele in Finland, throughout Europe, and worldwide. Its extensive product portfolio includes the iCare IC100 and IC200 tonometers, along with the iCare HOME device for personal eye pressure monitoring. Furthermore, the company provides sophisticated imaging technologies such as the iCare EIDON AF for confocal retinal imaging, DRSplus for screening diabetic retinopathy, the iCare MAIA microperimeter for precise visual field measurements, and iCare COMPASS, which facilitates fundus perimetry using true-color retinal images. Beyond hardware, Revenio also offers Oculo, a comprehensive eye care software platform that seamlessly integrates clinical communication, telehealth functionalities, remote patient monitoring, and robust data analytics. Established in 2001, Revenio Group Oyj is based in Vantaa, Finland.
IPO date
Jan 01, 2003
Employees
217
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT